Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2010 - 2026)

Pacific Biosciences Of California's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $782.4 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 9.11% year-over-year to $782.4 million in Q1 2026; TTM through Mar 2026 was $3.2 billion, a 37.11% decrease from a year earlier, with the FY2025 full-year figure at $784.1 million, down 37.79% from the prior year.
• Liabilities and Shareholders Equity steadied at $782.4 million in Q1 2026 per PACB's latest filing, from $784.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.9 billion in Q1 2022 and bottomed at $782.4 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2024), against an average of $1.5 billion.
• Across the five-year window, Liabilities and Shareholders Equity surged 56688.92% in 2022 and plunged 48.45% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then retreated by 1.19% to $1.7 billion in 2023, then fell by 27.81% to $1.3 billion in 2024, then plunged by 37.79% to $784.1 million in 2025, then dropped by 0.22% to $782.4 million in 2026.
• Per Business Quant, the three latest PACB Liabilities and Shareholders Equity figures stand at $782.4 million (Q1 2026), $784.1 million (Q4 2025), and $803.2 million (Q3 2025).